Answers are grounded in this paper and cite their sources.
Background/Objectives: Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions are equivocal, and the value of prostate-specific antigen density (PSAD) may depend on lesion zone. We compared whole-gland PSAD with transition-zone PSAD (TZ-PSAD) by lesion zone and quantified the yield of systematic biopsy. Methods: We retrospectively analyzed 542 men with a PI-RADS 3 index lesion who underwent MRI-targeted and 12-core systematic biopsy. Clinically significant prostate cancer (csPCa) was defined as ISUP grade group ≥ 2. Discrimination was assessed by ROC analysis; data-derived zonal thresholds were validated by bootstrap optimism correction. Results: csPCa was detected in 86 men (15.9%), in 18 (3.3%) by systematic cores alone. AUCs for PSAD and TZ-PSAD were 0.77 and 0.76 in peripheral-zone lesions (59 csPCa; p = 0.540) and 0.64 and 0.82 in transition-zone lesions (27 csPCa; p < 0.001). A zonal rule (PSAD ≥ 0.12 for peripheral-zone and TZ-PSAD ≥ 0.22 for transition-zone lesions) classified 214 men (39.5%) for deferral and missed four csPCa cases (sensitivity 95.3%; optimism-corrected 93.8%); a uniform TZ-PSAD ≥ 0.22 rule performed similarly. Conclusions: In this derivation cohort, TZ-PSAD performed at least as well as whole-gland PSAD, with the largest difference in transition-zone lesions. Systematic cores detected csPCa that targeted cores alone would have missed in 3.3% of men. The thresholds require external validation.
No takes yet. Share an insight, caveat, or question.
Soydaş et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: